Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2014, Article ID 141360, 7 pages
Research Article

Frequency and Prognostic Relevance of FLT3 Mutations in Saudi Acute Myeloid Leukemia Patients

1Department of Hematology and Blood Bank,Theodor Bilharz Research Institute, Giza 12411, Egypt, Egypt
2Department of Central Military Laboratory, Prince Sultan Military Medical City, P.O. Box 7897, Riyadh 11159, Saudi Arabia
3Department of Adult Clinical Hematology and Stem Cell Therapy, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
4Department of Pediatric Hematology/Oncology, Prince Sultan Military Medical City, P.O. Box 7897, Riyadh 11159, Saudi Arabia

Received 21 September 2013; Revised 21 December 2013; Accepted 12 January 2014; Published 20 February 2014

Academic Editor: Andreas Neubauer

Copyright © 2014 Ghaleb Elyamany et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The Fms-like tyrosine kinase-3 (FLT3) is a receptor tyrosine kinase that plays a key role in cell survival, proliferation, and differentiation of hematopoietic stem cells. Mutations of FLT3 were first described in 1997 and account for the most frequent molecular mutations in acute myeloid leukemia (AML). AML patients with FLT3 internal tandem duplication (ITD) mutations have poor cure rates the prognostic significance of point mutations; tyrosine kinase domain (TKD) is still unclear. We analyzed the frequency of FLT3 mutations (ITD and D835) in patients with AML at diagnosis; no sufficient data currently exist regarding FLT3 mutations in Saudi AML patients. This study was aimed at evaluating the frequency of FLT3 mutations in patients with AML and its significance for prognosis. The frequency of FLT3 mutations in our study (18.56%) was lower than many of the reported studies, FLT3-ITD mutations were observed in 14.4%, and FLT3-TKD in 4.1%, of 97 newly diagnosed AML patients (82 adult and 15 pediatric). Our data show significant increase of FLT3 mutations in male more than female (13 male, 5 female). Our results support the view that FLT3-ITD mutation has strong prognostic factor in AML patients and is associated with high rate of relapse, and high leucocytes and blast count at diagnosis and relapse.